Siebenmann C O, Barbara C
Bull World Health Organ. 1974;51(3):283-9.
Although the field trials carried out by the Medical Research Council of Great Britain demonstrated that BCG vaccination can confer a substantial degree of immunity against tuberculous infection, it does not follow that BCG substrains other than the one used for those trials will produce equally favourable results. In fact, there is increasing evidence that different BCG strains may differ widely in their protective potency. The experiments described here further confirm these differences. They also show how the determination of the minimum dose of a BCG vaccine capable of delaying the development of tuberculous infection in mice and in guinea-pigs can yield reproducible data that may help to characterize individual BCG strains.The main purpose of these experiments was to determine the protective potency of Connaught freeze-dried BCG vaccine, lot 140, and to compare it with that of three other BCG vaccines. Marked differences were found with respect to the minimum protective dose for mice or guinea-pigs and the degree of immunity and tuberculin allergy produced in guinea-pigs as shown by the dose-response relationships recorded over a wide dosage range. The results suggest that the Connaught vaccine equals or surpasses the other vaccines in effectiveness.Such tests require a reference BCG vaccine of high protective potency for both animals and man.
尽管英国医学研究理事会进行的现场试验表明，卡介苗接种可赋予对结核感染的高度免疫力，但这并不意味着用于这些试验的卡介苗菌株以外的其他菌株会产生同样良好的效果。事实上，越来越多的证据表明，不同的卡介苗菌株在其保护效力上可能有很大差异。这里描述的实验进一步证实了这些差异。它们还表明，确定能够延迟小鼠和豚鼠结核感染发展的卡介苗疫苗的最小剂量，如何能够产生可重复的数据，这可能有助于表征单个卡介苗菌株。这些实验的主要目的是确定康诺冻干卡介苗疫苗（批号140）的保护效力，并将其与其他三种卡介苗疫苗进行比较。如在很宽的剂量范围内记录的剂量反应关系所示，在小鼠或豚鼠的最小保护剂量以及豚鼠产生的免疫程度和结核菌素过敏方面发现了显著差异。结果表明，康诺疫苗在有效性方面等于或超过其他疫苗。此类试验需要一种对动物和人类都具有高保护效力的参考卡介苗疫苗。
